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Summary Chromosome 6q has been shown to be one of the most frequent sites for allelic loss in human breast cancer. The mannose 6-
phosphate/insulin-like growth factor 2 receptor (IGF2R) gene, which maps to chromosome 6q26-27, functions in the activation ofTGF-Pl, a
potent growth inhibitor for most cell types, the degradation of the mitogen IGF2 and the intracellular trafficking of lysosomal enzymes. Loss of
heterozygosity (LOH) at the IGF2R locus with mutations in the remaining allele have been reported in liver cancers and recently in two high-
grade cases of ductal carcinoma in situ of the breast. We have sought to confirm that allelic loss of IGF2R is an early event in the aetiology of
breast cancer by screening a group of 'early' lesions for LOH at a polymorphic microsatellite marker within the IGF2Rgene using polymerase
chain reaction (PCR). Several microdissected tumourfoci were analysed foreach of 40 mammographically detected invasive carcinomas and
22 cases of pure ductal carcinoma in situ (DCIS). None of 25 (62.5%) informative early invasive carcinomas showed any evidence of LOH.
This group comprised predominantly of well- to moderately differentiated cases (95%). However, 4 out of 18 informative DCIS cases (22%)
showed clear evidence of LOH. Three of these were poorly differentated (high-grade) lesions. These data suggest that loss of heterozygosity
at the IGF2Rgene is associated with poor differentiation at this early stage of breast cancer development and progression.
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Experimental evidence suggest that paracrine interactions between
stromal and epithelial cells influence the growth and malignant
behaviour ofbreast cancers (Singer et al, 1995). The use ofboth in
situ hybridization (Paik, 1992) and immunohistochemistry (Ellis
et al, 1994) have demonstrated that insulin-like growth factor 2
(IGF2) is expressed by fibroblasts in both benign and malignant
breast lesions. IGF2 is a potent mitogen for a number of breast
cancer epithelial cell lines in vitro and it is thought to exert its
mitogenic effect primarily through the high affinity insulin-like
growth factor 1 receptor (IGF1R). In contrast, binding ofIGF2 to
the mannose 6-phosphate/insulin-like growth factor 2 receptor
(IGF2R) results in internalization and subsequent degradation of
the ligand, making it unavailable to activate IGFIR. In addition,
the activation ofTGF-01, a potent growth inhibitor of epithelial
cells, is dependent on binding of the TGF-PI latent complex to
IGF2R (Dennis and Rifkin, 1991; Kornfeld, 1992). Thus IGF2R
effectively operates as a growth-suppressor gene by antagonizing
the growth stimulatory effect of IGF2 and activating the growth-
inhibitory effect ofTGF-pI.
IGF2R mRNA has been detected in breast cancer cell lines and
tissue (De Leon et al, 1988; Cullen et al, 1990). In situ hybridiza-
tion analyses ofbreast tumour biopsies identified a higher level of
expression in carcinomas than in the corresponding benign
epithelium or stroma (Zhoa et al, 1993) that would not support a
suppressor role for IGF2R. Comparisons of IGF2R RNA levels
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between tumour and non-tumour breast tissue using northern
analysis have demonstrated expression in all tissue tested with no
significant differences in the level of expression between tumour
and non-tumour tissue (Hebert et al, 1994). Analysis ofthe IGF2R
gene copy number in this same tumour group, showed no amplifi-
cation ofthe gene whatever the clinical presentation ofthe tumour
and irrespective ofa concomitant amplification ofc-erbB2 or int-2
genes in several tumours. These data might reflect groups of
tumours that do not involve IGF2R inactivation in their aetiology.
The IGF2R gene has been mapped to chromosome 6q26-27
(Laureys et al, 1988). Allelic loss at this region has been observed
previously in several tumour types, including ovarian carcinomas
(Rodabaugh et al, 1995), malignant melanomas (Millikin et al,
1991), renal cell carcinomas (Morita et al, 1991), small-cell lung
cancers (Merlo et al, 1994), T-cell acute lymphocytic leukaemias
(Menasce et al, 1994) and breast carcinomas (Devilee et al, 1991;
Orphanos et al, 1995). This shared region of allelic loss may
reflect the involvement of putative tumour-suppressor genes that
are pleiotrophic for these tumours. Detailed studies of chromo-
some 6q in breast cancer have highlighted two regions (6q13 and
6q26-27) that show high levels of loss of heterozygosity (LOH)
and indicate the presence of at least two tumour-suppressor genes
(Devilee et al, 1991; Orphanos et al, 1995).
De Souza et al (1995a,b) first demonstrated frequent LOH at
the IGF2R locus in human hepatocellular tumours and identified
point mutations in the remaining allele in 25% of these cases,
strongly suggesting that the IGF2R gene functions as a tumour-
suppressor gene in human livercarcinogenesis. Recently, the same
group also reported LOH for 12 out of 40 breast tumours studied
(Hankins et al, 1996). No clinical information was provided forthe
7 out of 21 informative invasive cases that showed LOH. Five
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ductal carcinoma in situ (DCIS) cases that showed LOH were
screened for mutations in the remaining allele. Two ofthese, both
comedo-type (high grade) cases, showed missense mutations
(Hankins et al, 1996) supporting the hypothesis that IGF2R allelic
loss may be an early event in the aetiology ofsome breast cancers.
Small, mammographically-detected breast cancers form a useful
group for study of the involvement of tumour-suppressor genes in
the development and earlier stages ofprogression ofbreast cancer.
We have previously identified frequent LOH at 6q25-27 in a group
of 'early' invasive carcinomas and preinvasive cases of DCIS
(Chappell et al, 1997), confirming distal chromosome 6q as amajor
site for genetic change in the early stages of development of some
sporadic breast cancers. Thepurpose ofthis study was toinvestigate
whether LOH occurs as frequently at the candidate tumour-
suppressor gene IGF2R in these early tumours, and ifso, ifthere is
any correlation with tumourtype. We analysed ahighly informative
dinucleotiderepeat/tetranucleotide deletion/insertionpolymorphism
(Hol etal, 1992) withinthe 3'untranslatedregionoftheIGF2Rgene
in multiple tumour foci prepared by microdissection for each of40
'early' invasive carcinomas and 22 cases ofpure DCIS.
MATERIALS AND METHODS
Patients
A total of40 invasive breast carcinomas that were impalpable and
detected by mammography were studied. All were from the preva-
lent round of screening and were detected by the Leicestershire
Breast Screening Service. Cases of 15 mm or less were examined.
All had either axillary node sampling or axillary dissection. None
of the tumours were from women with either a strong family
history of breast cancer or any known inherited predisposition to
the development oftumours. All but two were well- ormoderately
differentiated and all were node negative. A total of35 were infil-
trating ductal carcinomas with the remainder comprising three
tubular carcinomas and two infiltrating lobular carcinomas.
A total of22 cases ofpure DCIS were studied. These comprised
ten high-grade, three intermediate-grade and nine low-grade cases.
Tissues and histology
All tissues were fixed in 4% formaldehyde in saline for 18-36 h.
After a review of haematoxylin and eosin stained sections, repre-
sentative blocks were chosen for further study. All carcinomas
were reported according to the NHS Breast Screening Programme
National Coordinating Group for Breast Screening Pathology
Guidelines (1995). Infiltrating ductal carcinomas were graded
using the modified Bloom and Richardson system (Elston and
Ellis, 1991). Cases ofDCIS were graded as low-, intermediate- or
high-nuclear grade. All histology was undertaken by RA Walker.
DNA extraction and microdissection from paraffin
embedded sections
Formalin-fixed, paraffin-embedded tissue from breast tumour
samples and non-involved lymph nodes or normal breast served as
the source of tumour and normal DNA respectively. For each
tumour-normal pair, DNA was extracted from non-tumour tissue
and microdissected tumour foci prepared from 10jm paraffin-
embedded sections as described previously (Shaw et al, 1996;
Chappell et al, 1997).
Table 1 Clinicopathological features of early breast cancers showing
alterations at IGF2R
Case Type Grade Alteration
D2 DCIS High LOH
D4 DCIS Low LOH
D13 DCIS High LOH
D14 DCIS High LOH
55 IDC II MSI
DCIS, ductal carcinoma in situ; IDC, infiltrating ductal carcinoma; LOH, loss
of heterozygosity; MSI, microsatellite instability.
PCR analysis at IGF2R
PCRreaction components were as follows: 45 mM Tris hydrochloric
acid, pH 8.8; 11 mm ammonium sulphate; 4.5 mm magnesium
chloride, 200gM dT`P; dCTP; dGTP; 25 ,UM dATP (Pharmacia,
UK); 0.2gl [a-35S]deoxyadenosine-5'-triphosphate (600 Ci mmol-',
10 mCi ml-' (ICN Pharmaceuticals, UK); 113 jg ml-' bovine serum
albumin (Boehringher Mannheim); 6.7 mm ,-mercaptoethanol;
4.4jiM EDTA, pH 8.0; 10 pmol of both the forward (GTA TCA
TGA GAA CCT GAA GAG) and the reverse primer (TTG CCG
GCT GGT GAA TTC AA) (Hol etal, 1992); 100 ng ofDNA or 2jl
of microdissected DNA and 1 unit of Taq DNA polymerase (Gibco
BRL, UK) in a total volume of25 pl. Hot-start PCR was carried out
using the following: 5 min denaturation at 94°C, followed by 30
cycles of 1 min denaturation at94°C, 1 min annealing at65°C, and 1
min extension at 72°C with a final extension of 7 min at 72°C on a
DNA Thermal Cycler (Perkin Elmer Cetus, UK). Analysis of PCR
products and interpretation of LOH were as described previously
(Shaw et al, 1996, Chappell et al, 1997).
RESULTS
We have analysed 62 'early' breast carcinomas comprising 40
invasive carcinomas and 22 cases of pure DCIS for LOH at
IGF2R. Because of the complex heterogeneity of the disease and
the presence of non-tumour cells, we carried out LOH analysis on
DNA extracted from different foci that had been microdissected
from within the same tumour tissue section. Cases that were
homozygous at the IGF2R polymorphic repeat (Figure lA) were
considered uninformative. The frequency ofheterozygosity varied
between the two groups: 25 of the 'early' invasive cases (62.5%)
and 18 of the 22 preinvasive cases of DCIS (82%) were informa-
tive. Ofthe total 43 cases (69%) that were informative five showed
alterations at IGF2R. The clinicopathological features of these
cases are summarized in Table 1.
The group of 'early' invasive carcinomas were predominantly
well- or moderately differentiated cases (95% grade 1 or grade 2).
None of these tumours showed any evidence of LOH at IGF2R,
although one cases showed clear evidence of microsatellite insta-
bility (Figure iB). In contrast, 4 of the 18 informative DCIS cases
(22%) showed clear evidence of LOH. For example, Figure IC
shows DCIS cases 2 that exhibited loss ofboth the upper and lower
allele in separate microdissected tumour ducts. Figure ID shows
DCIS case 4 with clear loss of the upper allele in all ducts exam-
ined. Three ofthe fourcases ofDCIS with LOH were high nuclear-
grade cases, and one case was low grade (Table 1), suggesting an
association between LOH at IGF2R and poor differentiation in the
early stages ofbreast cancer development and progression.
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Figure 1 Representative examples of LOH at the IGF2Rlocus in 'early' breast
cancers. N, normal tissue; T, tumourtissue. (A) Two non-informative invasive
carcinoma patients; (B) informative early invasive carcinoma showing
microsatellite instability; (C and D) DCIS cases 2 and 4, respectively, with LOH
DISCUSSION
In this study we examined 'early' breast carcinomas for loss of
heterozygosity at a polymorphic microsatellite locus within the 3'
untranslated region of the IGF2R gene on chromosome 6q26-27.
DNA samples extracted from microdissected tumour foci prepared
from 10 gm paraffin-embedded tumour tissue sections were exam-
ined separately. We found a difference in the frequency of LOH
between the two groups of early lesions studied. None of the 40
early invasive carcinomas showed any evidence of allele loss,
although one case showed microsatellite instability. This case has
been reported previously and shows instability at nine out of ten
other loci tested (Shaw et al, 1996). The group of 'early' invasive
carcinomas were predominantly grade 1 or grade 2 cases (95%),
suggesting no involvement or inactivation of IGF2R in well- to
moderately differentiated tumours. In contrast, 4 out of 18 infor-
mative cases of DCIS showed clear evidence of LOH. Although
the DCIS lesions represent a pre-invasive stage of breast cancer,
10 out of the 22 cases examined were high nuclear grade, which is
recognized as a more aggressive form of the disease (Lagios,
1990). Three of the four DCIS tumours that showed LOH were
from the ten high-grade cases, suggesting an association between
inactivation of IGF2R and poorly differentiated in situ lesions.
These data support the findings of Hankins et al (1996), who
reported LOH with missense mutations in the remaining allele in
two comedo-type (high-grade) DCIS cases. In combination, these
data suggest that inactivation of IGF2R may occur only within
certain more aggressive subgroups (poorly differentiated cases) of
these 'early' breast cancers. Unfortunately, we were not able to
undertake sequence analysis of the remaining allele in those cases
that showed LOH because of the paucity of available DNA,
prepared by microdissection, for analysis of the large IGF2R gene.
The IGF2R gene was first identified as a tumour-suppressor
gene in hepatocellular tumours (De Souza et al, 1995b) and the
presence of LOH at the IGF2R locus in adenomas suggests that
inactivation may be an early event in liver carcinogenesis. The
datareported in this paper, taken togetherwith thatofHankins et al
(1996), would support a similar early involvement ofIGF2R inac-
tivation in certain pathways in the development and progression of
breast cancer. Additional evidence, suggesting a role for the
IGF2R gene in mammary carcinogenesis, comes from two other
key investigations. Jirtle et al (1993) first demonstrated that
steady-state IGF2R mRNA levels in rat mammary tumours,
regressing in response to d-limonene, increased twofold when
compared with untreated tumours and that in unresponsive
tumours expression of IGF2R was unaltered. More recently, Ellis
et al (1996), have shown that the affinity of IGF2 for IGF2R
inhibits IGF2 activity in MCF-7 breast cancer cells. Cellular
proliferation, receptor tyrosine kinase-dependent signalling and
extracellular IGF2 protein accumulation were all reduced specifi-
cally in the presence ofIGF2R afflnity. Therefore, by operating as
an IGF2 anatagonist the IGF2R gene has tumour suppressor-like
properties.
The lack of detection of LOH in the early invasive group of
cases does not appear to result from technical problems in inter-
pretation ofLOH data (e.g. masking ofany lost alleles by contam-
inating non-tumour material) as the same DNA samples prepared
by microdissection from these carcinomas show clear LOH with
three other microsatellite markers (ESR, D6S186, D6S193) that
map to 6q25.1-q27 (Chappell et al, 1997). Moreover, the group of
DCIS cases has previously been studied and also showed more
frequent LOH (50%) with the three other markers. The frequent
LOH detected within 6q25.1-27 could therefore indicate the
critical inactivation of other unknown tumour-suppressor genes
within this chromosomal interval (Chappell et al, 1997).
One factor that might interfere with the detection ofLOH in this
study is when polymerase amplification of dinucleotide repeats
produces slippage bands below the true allele (Louis et al, 1992).
Given that for a high proportion ofthe cases heterozygous for the
IGF2R dinucleotide repeat, the two alleles differed by only 2 bp in
length, any slippage bands would tend to mask loss ofthe smaller
allele andhence reduce the true frequency ofallelic loss. However,
one of our DCIS cases that showed LOH (Figure IC) had clearly
lost both the upper and lower allele in different microdissected
tumourducts. Othermechanisms thatdo notinvolve LOH but also
lead to inactivation of tumour-suppressor genes might also be
critical for inactivation of IGF2R in breast carcinogenesis. For
example, aberrant hypermethylation of 5' CpG islands within
proximal promoterregions has been implicated as a mechanismby
which tumour-suppressor genes can be inactivated. This has been
demonstrated for E-cadherin (Graff et al, 1995) and for the VHL
andp16tumour-suppressorgenes (Herman et al, 1994; Merlo et al,
1995). Therefore, it would be of interest to investigate the CpG
island methylation status within the 5' regulatory region of the
IGF2R gene.
Our study has been concerned with breast cancers at an 'early'
stage: small, node-negative invasive cases that have features asso-
ciated with a good prognosis appear to show no evidence ofLOH
at IGF2R, whereas high-grade cases of DCIS although at a pre-
invasive stage show evidence of LOH. These data provide good
evidence that IGF2R acts as a tumour-suppressor gene in the
development of some early breast cancers associated with a more
aggressive disease type.
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